Skip to content

Evaluation of the efficacy of adding Domperidone for the treatment of refractory gastroesophageal reflux disease

Evaluation of the efficacy of adding Domperidone to a proton pump inhibitor for the treatment of refractory gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017052134070N1
Enrollment
40
Registered
2017-06-09
Start date
2016-12-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-oesophageal reflux disease. Gastro-oesophageal reflux disease

Interventions

Intervention 1: Intervention group: pantoprazole 40mg (BD) + Domperidone 10mg (TID). Intervention 2: Control group: pantoprazole 40mg (BD) + placebo tablet (TID).
Treatment - Drugs
Intervention group: pantoprazole 40mg (BD) + Domperidone 10mg (TID)
Control group: pantoprazole 40mg (BD) + placebo tablet (TID)

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with gastroesophageal reflux disease that do not partially or completely respond to treatment after taking twice daily proton pump inhibitor for one month Exclusion criteria: age below 18 or above 80 years; severe cardiopulmonary, renal or liver failure; pregnancy; breast feeding; history of gastro-esophageal surgery or malignancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response to treatment. Timepoint: One month after starting therapy. Method of measurement: questionnnaires.

Secondary

MeasureTime frame
Quality of life. Timepoint: One month after starting tratment. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Tarang Taghvaei

Mazandaran University of Medical Sciences

tarang_taghvaei@yahoo.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026